Data as of Apr 17
| -0.14 / -0.60%|
The 4 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 33.00, with a high estimate of 37.00 and a low estimate of 28.00. The median estimate represents a +42.55% increase from the last price of 23.15.
The current consensus among 5 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.